NCT06987851View on ClinicalTrials.gov

An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD

PHASE3CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

March 22, 2022

Primary Completion Date

May 16, 2024

Study Completion Date

May 16, 2024

Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL

Divozilimab

Intravenous infusion of BCD-132 every 24 weeks

Trial Locations (15)

Unknown

Vyacheslav Andreyevich Dudin, Kirov

Dmitry Vladimirovich Pokhabov, Krasnoyarsk

Ivan Aleksandrovich Shchukin, Moscow

Sergey Viktorovich Kotov, Moscow

Elena Vladimirovna Parshina, Nizhny Novgorod

Irina Aleksandrovna Sokolova, Nizhny Novgorod

Gennady Nikolayevich Mishin, Pyatigorsk

Yuri Vladimirovich Trinitatsky, Rostov-on-Don

Zoya Aleksandrovna Goncharova, Rostov-on-Don

Leonid Grigoryevich Zaslavsky, Saint Petersburg

Natalya Agafonovna Totolyan, Saint Petersburg

Irina Yevgenyevna Poverennova, Samara

Valentina Mikhaylovna Alifirova, Tomsk

Stella Anatolyevna Sivertseva, Tyumen

Irina Vladimirovna Greshnova, Ulyanovsk

Sponsors

Lead Sponsor

Biocad
All Listed Sponsors
lead

Biocad

INDUSTRY

NCT06987851 - An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD | Biotech Hunter | Biotech Hunter